Devarati Mitra, M.D., Ph.D.
Department of Radiation Oncology, Division of Radiation Oncology
About Dr. Devarati Mitra
Dr. Devarati Mitra received her MD and PhD at Harvard Medical School before completing her residency training at the Harvard Radiation Oncology Program, working at Dana Farber Cancer Institute and Massachusetts General Hospital Cancer Center. She is now an Assistant Professor in the Department of Radiation Oncology at the University of Texas MD Anderson Cancer Center.
In her appointment to the Melanoma & Sarcoma Radiation Oncology section she specializes in the treatment of patients with melanoma, non-melanoma skin malignancies and bone or soft tissue sarcoma. Her clinical focus is on providing personalized patient care that brings the optimal radiation therapy approach to each patient’s unique cancer experience.
Her research is focused on how to combine modern radiation approaches with novel systemic therapies, including immunotherapy and molecularly targeted agents. She has received research funding from multiple extramural sources including the National Institutes of Health (NIH), American Society for Radiation Oncology (ASTRO) and American Society for Clinical Oncology (ASCO). Her research has been published across a variety of peer-reviewed journals and she is working on several clinical trials to continue to improve outcomes for cancer patients.
Read More
Present Title & Affiliation
Primary Appointment
Voluntary Clinical Assistant Professor, Division of Radiation Oncology, The University of Houston College of Medicine, Houston, TX
Assistant Professor, Department of Radiation Oncology, Division of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX
Dual/Joint/Adjunct Appointment
Voluntary Clinical Assistant Professor, The University of Houston College of Medicine, Houston, TX
Assistant Professor, Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX
Education & Training
Degree-Granting Education
| 2014 | Harvard Medical School, Boston, Massachusetts, US, MD |
| 2012 | Harvard University, Boston, Massachusetts, US, Ph.D. in Biology & Biomedical Sciences |
| 2006 | Stanford University, Stanford, California, US, BS in Biological Sciences |
Postgraduate Training
| 2015-2019 | Clinical Residency, Radiation Oncology, Harvard Radiation Oncology Program, Boston, Massachusetts |
| 2014-2015 | Clinical Internship, Internal Medicine, Brigham & Women's Hospital, Boston, Massachusetts |
Board Certifications
| 2021 | American Board of Radiology |
Experience & Service
Administrative Appointments/Responsibilities
Mel/ Sarc Section Research Director, Department of Radiation Oncology Clinical Research Council, The University of Texas MD Anderson Cancer Center, Houston, TX, 2022 - Present
Associate Director of Medical Student Education, The University of Texas MD Anderson Cancer Center, Houston, TX, 2021 - Present
Other Appointments/Responsibilities
Associate Faculty Member, The University of Texas MD Anderson Cancer Center UT Health Houston Graduate School of Biomedical Sciences, Houston, TX, 2023 - Present
Member, Graduate School of Biomedical Sciences, The University of Texas Health Science Center at Houston, Houston, TX, 2023 - Present
Residency Education Case Conference Coordinator, Harvard Radiation Oncology Program, Cambridge, MA, 2018 - 2019
Medical Student Education Coordinator, Harvard Radiation Oncology Program, Cambridge, MA, 2018 - 2019
Non-Resident Tutor, Harvard University, Cambridge, MA, 2014 - 2018
Teaching Assistant, Patient- Doctor 2, Harvard Medical School, Cambridge, MA, 2013 - 2014
Teaching Assistant, Translational Pharmacology, Harvard Medical School, Cambridge, MA, 2011 - 2011
Doctoral Student Teaching Assistant, Molecular Basis of Disease, Harvard Medical School, Cambridge, MA, 2009 - 2011
Doctoral Student Teaching Assistant, Molecular Cell Biology, Harvard Medical School, Cambridge, MA, 2009 - 2011
Undergraduate Alumni Interviewer, Stanford University, Stanford, CA, 2008 - Present
Resident Tutor, Harvard University, Cambridge, MA, 2008 - 2014
Institutional Committee Activities
Member, NRG FLASH Group, 2024 - Present
Member, NCCN Melanoma: Cutaneous Guidelines Committee, 2024 - Present
Melanoma Panel Member, Melanoma Multidisciplinary Network Conference, 2023 - Present
Member, MRF Mucosal Melanoma Translational Working Group, 2023 - Present
Member, Scientific Review Committee, 2023 - Present
Radiation Oncology Lead, Cutaneous Melanoma Algorithm Review Committee, 2023 - Present
Member, MCC International Planning Committee, 2023 - 2024
Member, Advanced Radiation Oncology Fellowship Interview Committee, 2022 - Present
Member, The Art and Science of Managing the New Melanoma Landscape Planning Committee, 2022 - 2022
Chair, Faculty & Non-Faculty Seed Award Scientific Review Committee, 2021 - 2021
Member, Joint Madrid MD Anderson Committee, 2021 - 2022
Co-chair, Non-melanoma Skin Cancer MD Anderson CME Conference, 2021 - 2021
Member, Melanoma CME Conference Planning Committee, 2021 - 2021
Member, Sarcoma Multidisciplinary Planning Conference, 2021 - 2023
Member, MD Anderson Research Foundations Pilot Testing, 2021 - 2021
Chair, ROSI Boot Walk Faculty and Non-faculty Seed Awards Committee, 2021 - 2021
Melanoma/Sarcoma Section Liaison, RayStation Electron Planning Transition Team, 2020 - 2021
Committee Member, ROSI Non Faculty Seed Award Scientific Review Committee, 2020 - 2020
Melanoma/Sarcoma Representative, Radiation Oncology Clinical Research Committee, 2020 - Present
Team Member, Radiation Oncology Covid Recovery Workstream – Virtual Care, 2020 - 2020
Honors & Awards
| 2024 | Andrew Sabin Family Fellow, The University of Texas MD Anderson Cancer Center |
| 2023 | Gilbert Fletcher Rising Stars Award, The University of Texas MD Anderson Cancer Center |
| 2023 | RSNA Scholar Award, Radiological Society of North America |
| 2019 | ASCO Young Investigator Award, American Society of Clinical Oncology |
| 2018 | Conquer Cancer Foundation Merit Award, Clinical Immuno-Oncology Symposium |
| 2018 | ASTRO Resident Seed Grant, American Society of Radiation Oncology |
| 2018 | Conquer Cancer Foundation Merit Award, American Society of Clinical Oncology |
| 2018 | William Shipley Research Award, Massachusetts General Hospital |
| 2018 | ASCO Young Investigator Award, American Society of Clinical Oncology |
| 2017 | ASTRO Resident Seed Grant, American Society of Radiation Oncology |
| 2014 | F30 Ruth L. Kirschstein National Research Service Award Individual Predoctoral Fellowship, National Institute of Environmental Health Sciences |
| 2013 | F30 Ruth L. Kirschstein National Research Service Award Individual Predoctoral Fellowship, National Institute of Environmental Health Sciences |
| 2012 | F30 Ruth L. Kirschstein National Research Service Award Individual Predoctoral Fellowship, National Institute of Environmental Health Sciences |
| 2011 | AACR Conference on Frontiers in Basic Cancer Research, American Association for Cancer Research |
| 2006 | Goldwater Scholarship, Barry Goldwater Scholarship and Excellence in Education Program |
| 2006 | Phi Beta Kappa National Honor Society, Phi Beta Kappa National Honor Society |
| 2006 | Graduated Summa Cum Laude in Biological Sciences, Stanford University |
| 2005 | Goldwater Scholarship, Barry Goldwater Scholarship and Excellence in Education Program |
| 2002 | Maryland Distinguished Scholar, Maryland |
| 2002 | National Merit Scholarship, National Merit Scholarship Corporation |
| 2002 | United States Marine Corps Scholastic Excellence Award, United States Marine Corps |
| 2002 | National AP Scholar, The College Board |
Professional Memberships
Selected Publications
Peer-Reviewed Articles
- Keatts SA, Salem AF, Swanson DM, Farooqi AS, Bishop AJ, Amaria RN, McQuade JL, Glitza Oliva IC, Diab A, Weiser R, Fisher SB, Goepfert RP, Ross MI, Ashleigh Guadagnolo B, Mitra D. Durable local control with hypofractionated radiation therapy for unresectable or metastatic melanoma. Clin Transl Radiat Oncol 49(None):100856, 2024. PMID: 39308633.
- Liu K, Waldrop T, Aguilar E, Mims N, Neill D, Delahoussaye A, Li Z, Swanson D, Lin SH, Koong AC, Taniguchi CM, Loo BW Jr, Mitra D, Schuler E. Redefining FLASH Radiation Therapy: The Impact of Mean Dose Rate and Dose Per Pulse in the Gastrointestinal Tract. Int J Radiat Oncol Biol Phys None(None):None, 2024. PMID: 39424078.
- Yoder AK, Farooqi A, Mitra D, Livingston JA, Araujo DM, Sturgis EM, Goepfert R, Bishop AJ, Guadagnolo BA. Outcomes for Patients With Head and Neck Sarcoma Treated Curatively With Radiation Therapy and Surgery. Pract Radiat Oncol 14(5):e373-e382, 2024. PMID: 38851534.
- Bishop AJ, Mitra D, Farooqi A, Swanson DM, Hempel C, Willis T, Pearlnath C, Wang WL, Ratan R, Somaiah N, Benjamin RS, Torres KE, Hunt KK, Scally CP, Keung EZ, Satcher RL, Bird JE, Lin PP, Moon BS, Lewis VO, Roland CL, Guadagnolo BA. Moderately hypofractionated, preoperative radiotherapy in patients with soft tissue sarcomas (HYPORT-STS): Updated local control, late toxicities, and patient-reported outcomes. Cancer None(None):None, 2024. PMID: 39192597.
- Nasr LF, Zoghbi M, Lazcano R, Nakazawa M, Bishop AJ, Farooqi A, Mitra D, Guadagnolo BA, Benjamin R, Patel S, Ravi V, Araujo DM, Livingston A, Zarzour MA, Conley AP, Ratan R, Somaiah N, Lazar AJ, Roland C, Keung EZ, Nassif Haddad EF. High-Grade Pleomorphic Sarcomas Treated with Immune Checkpoint Blockade: The MD Anderson Cancer Center Experience. Cancers (Basel) 16(9), 2024. PMID: 38730715.
- Farooqi AS, Yoder AK, Lin HY, Pasalic D, Erasmus J, Betancourt S, Wernz C, Mitra D, Zarzour MA, Somaiah N, Conley A, Ratan R, Livingston A, Araujo DM, Roland C, Scally C, Keung E, Gandhi SN, Ashleigh Guadagnolo B, Nguyen QN, Bishop AJ. SABR for Sarcoma Lung Metastases: Indications for Treatment and Guidance for Patient Selection. Int J Radiat Oncol Biol Phys 118(4):971-978, 2024. e-Pub 2023. PMID: 37914142.
- Cass S, Cope B, Bishop AJ, Chiang YJ, Ashleigh Guadagnolo B, Farooqi A, Morrison W, Witt RG, Seervai RNH, Garden AS, Fuller CD, Goepfert RP, Ross M, Gershenwald JE, Wong M, Aung PP, Keung EZ, Mitra D. Primary tumor site for localized Merkel cell carcinoma drives different management strategies without impacting oncologic outcomes. Radiother Oncol 188:109892, 2023. e-Pub 2023. PMID: 37659660.
- Chau BL, LaGuardia JS, Kim S, Zhang SC, Pletcher E, Sanford NN, Raldow AC, Singer L, Gong J, Padda SK, Kamrava M, Cohen T, Mitra D, Atkins KM. Association of Parental Status and Gender With Burden of Multidisciplinary Tumor Boards Among Oncology Physicians. JAMA Netw Open 6(10):e2340663, 2023. e-Pub 2023. PMID: 37906191.
- Yoder AK, Farooqi AS, Wernz C, Subramaniam A, Ravi V, Goepfert R, Sturgis EM, Mitra D, Bishop AJ, Guadagnolo BA. Outcomes after definitive treatment for cutaneous angiosarcomas of the face and scalp: Reevaluating the role of surgery and radiation therapy. Head Neck 45(8):1943-1951, 2023. e-Pub 2023. PMID: 37272774.
- Guadagnolo BA, Bassett RL, Mitra D, Farooqi A, Hempel C, Dorber C, Willis T, Wang WL, Ratan R, Somaiah N, Benjamin RS, Torres KE, Hunt KK, Scally CP, Keung EZ, Satcher RL, Bird JE, Lin PP, Moon BS, Lewis VO, Roland CL, Bishop AJ. Hypofractionated, 3-week, preoperative radiotherapy for patients with soft tissue sarcomas (HYPORT-STS): a single-centre, open-label, single-arm, phase 2 trial. Lancet Oncol 23(12):1547-1557, 2022. e-Pub 2022. PMID: 36343656.
- Mitra D, Farr M, Nagarajan P, Ho J, Bishop AJ, Jhingran A, Farooqi AS, Frumovitz M, Amaria RN, McQuade JL, Jazaeri AA, Guadagnolo BA. Gynecologic tract melanoma in the contemporary therapeutic era: high rates of local and distant disease progression. Gynecol Oncol 167(3):483-489, 2022. e-Pub 2022. PMID: 36229264.
- Bishop AJ, Amini B, Lin H, Raza SM, Patel S, Grosshans DR, Ghia A, Farooqi A, Guadagnolo BA, Mitra D, Akdemir KC, Lazar AJ, Wang WL, Alvarez-Breckenridge C, Bird J, Rhines LD, Somaiah N, Conley AP. Immune Checkpoint Inhibitors Have Clinical Activity in Patients With Recurrent Chordoma. J Immunother 45(8):374-378, 2022. e-Pub 2022. PMID: 35943386.
- Bishop AJ, Zheng J, Subramaniam A, Ghia AJ, Wang C, McGovern SL, Patel S, Guadagnolo BA, Mitra D, Farooqi A, Reardon MJ, Kim B, Guha-Thakurta N, Li J, Ravi V. Cardiac Angiosarcomas: Risk of Brain Metastasis and Hemorrhage Warrants Frequent Surveillance Imaging and Early Intervention. Am J Clin Oncol 45(6):258-263, 2022. e-Pub 2022. PMID: 35588225.
- Mitra D. Locoregional-Directed Therapy Is Still a Cornerstone of Anorectal Melanoma Management. Int J Radiat Oncol Biol Phys 112(5):1075, 2022. PMID: 35286880.
- Mitra D, Rao PK, Nagarajan P, Bishop AJ, Farooqi AS, Gershenwald JE, Wargo J, Keung EZ, Fisher SB, Amaria RN, Davies MA, Ross MI, Guadagnolo BA. Outcomes After Sphincter-Sparing Local Therapy for Anorectal Melanoma: 1989 to 2020. Pract Radiat Oncol 12(5):437-445, 2022. e-Pub 2022. PMID: 35278716.
- Boyce-Fappiano D, Damron EP, Farooqi A, Mitra D, Conley AP, Somaiah N, Araujo DM, Livingston JA, Ratan R, Keung EZ, Roland CL, Guadagnolo BA, Bishop AJ. Hypofractionated radiation therapy for unresectable or metastatic sarcoma lesions. Adv Radiat Oncol 7(3):100913, 2022. e-Pub 2022. PMID: 35647398.
- Ho J, Mattei J, Tetzlaff M, Williams MD, Davies MA, Diab A, Oliva ICG, McQuade J, Patel SP, Tawbi H, Wong MK, Fisher SB, Hanna E, Keung EZ, Ross M, Weiser R, Su SY, Frumovitz M, Meyer LA, Jazaeri A, Pettaway CA, Guadagnolo BA, Bishop AJ, Mitra D, Farooqi A, Bassett R, Faria S, Nagarajan P, Amaria RN. Neoadjuvant Checkpoint Inhibitor Immunotherapy for Resectable Mucosal Melanoma. Front Oncol 12:1001150, 2022. e-Pub 2022. PMID: 36324592.
- Mitra D, Ologun G, Keung EZ, Goepfert RP, Amaria RN, Ross MI, Gershenwald JE, Lucci A, Fisher SB, Davies MA, Lee JE, Bishop AJ, Farooqi AS, Wargo J, Guadagnolo BA. Nodal Recurrence is a Primary Driver of Early Relapse for Patients with Sentinel Lymph Node-Positive Melanoma in the Modern Therapeutic Era. Ann Surg Oncol 28(7):3480-3489, 2021. e-Pub 2021. PMID: 33856603.
- Mitra D, Devlin PM, Buzurovic I, Thornton K, Lam AC, Raut CP, Baldini EH, Lam MB. Clinical outcomes following high-dose-rate surface applicator brachytherapy for angiosarcoma of scalp and face. J Contemp Brachytherapy 13(2):172-178, 2021. e-Pub 2021. PMID: 33897791.
- Boyce-Fappiano D, Guadagnolo BA, Ratan R, Wang WL, Wagner MJ, Patel S, Livingston JA, Lin PP, Diao K, Mitra D, Farooqi A, Lazar AJ, Roland CL, Bishop AJ. Evaluating the Soft Tissue Sarcoma Paradigm for the Local Management of Extraskeletal Ewing Sarcoma. Oncologist 26(3):250-260, 2021. e-Pub 2020. PMID: 33289298.
- Lee G, Kim DW, Muralidhar V, Mitra D, Horick NK, Eyler CE, Hong TS, Drapek LC, Allen JN, Blaszkowsky LS, Giantonio B, Parikh AR, Ryan DP, Clark JW, Wo JY. Chemoradiation-related lymphopenia and its association with survival in patients with squamous cell carcinoma of the anal canal. Oncologist 25(12):1015-1022, 2020. e-Pub 2020. PMID: 32827337.
- Mitra D, Devlin PM, Buzurovic I, Thornton K, Lam AC, Raut CP, Baldini EH, Lam MB. Clinical outcomes following HDR surface applicator brachytherapy for angiosarcoma of the scalp and face. J Contemp Brachytherapy 2020:7615248. e-Pub 2020. PMID: None.
- Yerramilli D, Drapek L, Nipp RD, Horick N, Moran SMC, Noé B, D'Arpino SM, Mitra D, Hong TS, Ryan DP, Dizon DS, Wo J. Sexual Function, Quality of Life, and Mood After Radiation Therapy in Patients with Anal Cancer. J Gastrointest Cancer 51(1):204-210, 2020. e-Pub 2019. PMID: 30980294.
- Mitra D, Pei Y, Buzurovic I, Devlin PM, Thornton K, Raut CP, Baldini EH, Lam MB. Angiosarcoma of the Scalp and Face: A Dosimetric Comparison of HDR Surface Applicator Brachytherapy and VMAT. Sarcoma 2020:7615248, 2020. e-Pub 2020. PMID: 32908445.
- Mitra, D, Chen, YH, Li, R, Hermann, G, Atkins, KM, Kozono, D, Baldini, EH, Aizer, A, Chukwueke, U, Mak, RH. EGFR mutant locally advanced non-small cell lung cancer is at increased risk of brain metastasis. Clinical and Translational Radiation Oncology 18:32-38, 2019. PMID: 31341973.
- Mitra D, Chen YH, Li R, Hermann G, Atkins K, Kozono D, Baldini EH, Aizer A, Chukwueke U, Mak RH. EGFR mutant locally advanced non-small cell lung cancer is at increased risk of brain metastasis. Clin Transl Radiat Oncol 18:32-38, 2019. PMID: None.
- Mito JK, Mitra D, Barysauskas CM, Mariño-Enriquez A, Morgan EA, Fletcher CDM, Raut CP, Baldini EH, Doyle LA. A Comparison of Outcomes and Prognostic Features for Radiation-Associated Angiosarcoma of the Breast and Other Radiation-Associated Sarcomas. Int J Radiat Oncol Biol Phys 104(2):425-435, 2019. e-Pub 2019. PMID: 30703514.
- Mitra D, Horick N, Brackett DG, Mouw KW, Hornick JL, Ferrone S, Hong TS, Mamon H, Clark JW, Parikh AP, Allen JN, Ryan DP, Ting DT, Deshpande W, Wo JY. High IDO1 expression is associated with poor outcome in anal cancer patients treated with definitive chemoradiotherapy. Oncologist 24(6):e275-e283, 2019. PMID: 30755500.
- Mitra D, Clark JW, Shih HA, Oh KS, Brastianos PK, Wo JY, Strickland MR, Curry WT, Parikh AR, Corcoran RB, Ryan DP, Iafrate AJ, Borger DR, Lennerz JK, Hong TS. Enrichment of Her2 amplification in brain metastases from primary gastrointestinal malignancies. Oncologist 24(2):193-201, 2019. e-Pub 2018. PMID: 30373904.
- Fitarelli-Kiehl M, Ashtaputre R, Yu F, Supplee J, Paweletz C, Mitra D, Schoenfeld JD, Sarh P, Makrigiorgos GM. DNA end-repair and denaturation enhances digital droplet PCR-based analysis of small input liquid biopsies. Clin Chem 64(12):1762-1771, 2018. e-Pub 2018. PMID: 30274976.
- Rose B, Mitra D, Hong TS, Jee KW, Niemierko A, Drapek LN, Blaszkowsky LS, Allen JN, Murphy JE, Clark JW, Ryan DP, Wo JY. Irradiation of anatomically defined pelvic subsites and acute hematologic toxicity in anal cancer patients undergoing chemoradiation. Pract Radiat Oncol 7(5):e291-e297, 2017. e-Pub 2017. PMID: 28462895.
- Mitra D, Hong TS, Horick N, Rose B, Drapek LN, Blaszkowsky LS, Allen JN, Kwak EL, Murphy JE, Clark JW, Ryan DP, Cusack JC, Bordeianou LG, Berger DL, Wo JY. Long-term outcomes and toxicities of a large cohort of anal cancer patients treated with dose-painted IMRT per RTOG 0529. Adv Radiat Oncol 2(2):110-117, 2017. e-Pub 2017. PMID: 28740921.
- Shen CH, Kim SH, Trousil S, Frederick DT, Piris A, Yuan P, Cai L, Gu L, Li M, Lee JH, Mitra D, Fisher DE, Sullivan RJ, Flaherty KT, Zheng B. Loss of cohesin complex components STAG2 or STAG3 confers resistance to BRAF inhibition in melanoma. Nat Med 22(9):1056-61, 2016. e-Pub 2016. PMID: 27500726.
- Mitra D, Catalano PJ, Cimbak N, Damato AL, Muto MG, Viswanathan AN. The risk of lymphedema after postoperative radiation therapy in endometrial cancer. J Gynecol Oncol 27(1):e4, 2016. e-Pub 2015. PMID: 26463430.
- Mitra D, Nout R, Catalano PJ, Creutzberg C, Cimbak N, Lee L, Viswanathan AN. Rectal bleeding after radiation therapy for endometrial cancer. Radiother Oncol 115(2):240-5, 2015. e-Pub 2015. PMID: 26003340.
- Cooper ZA, Juneja VR, Sage PT, Frederick DT, Piris A, Mitra D, Lo JA, Hodi FS, Freeman GJ, Bosenberg MW, McMahon M, Flaherty KT, Fisher DE, Sharpe AH, Wargo JA. Response to BRAF inhibition in melanoma is enhanced when combined with immune checkpoint blockade. Cancer Immunol Res 2(7):643-54, 2014. e-Pub 2014. PMID: 24903021.
- Luo X, Mitra D, Sullivan RJ, Wittner BS, Kimura AM, Pan S, Hoang MP, Brannigan BW, Lawrence DP, Flaherty KT, Sequist LV, McMahon M, Bosenberg MW, Stott SL, Ting DT, Ramaswamy S, Toner M, Fisher DE, Maheswaran S, Haber DA. Isolation and molecular characterization of circulating melanoma cells. Cell Rep 7(3):645-53, 2014. e-Pub 2014. PMID: 24746818.
- Liu S, Wang J, Su Y, Guerrero C, Zeng Y, Mitra D, Brooks PJ, Fisher DE, Song H, Wang Y. Quantitative assessment of Tet-induced oxidation products of 5-methylcytosine in cellular and tissue DNA. Nucleic Acids Research 41(13):6421-9, 2013. PMID: 23658232.
- Frederick DT, Piris A, Cogdill AP, Cooper ZA, Lezcano C, Ferrone CR, Mitra D, Boni A, Newton LP, Liu C, Peng W, Sullivan RJ, Lawrence DP, Hodi FS, Overwijk WW, Lizée G, Murphy GF, Hwu P, Flaherty KT, Fisher DE, Wargo JA. BRAF Inhibition Is Associated with Enhanced Melanoma Antigen Expression and a More Favorable Tumor Microenvironment in Patients with Metastatic Melanoma. Clinical Cancer Research 19(5):1225-31, 2013. PMID: 23307859.
- Mitra D, Luo X, Morgan A, Wang J, Hoang MP, Lo J, Guerrero CR, Lennerz JK, Mihm MC, Wargo JA, Robinson KC, Devi SP, Vanover JC, D'Orazio JA, McMahon M, Bosenberg MW, Haigis KM, Haber DA, Wang Y, Fisher DE. An ultraviolet-radiation-independent pathway to melanoma carcinogenesis in the red hair/fair skin background. Nature 491(7424):449-453, 2012. PMID: 23123854.
- Levine CG, Mitra D, Sharma A, Smith CL, Hegde RS. The efficiency of protein compartmentalization into the secretory pathway. Molecular Biology of the Cell 16(1):279-91, 2005. PMID: 15496459.
- Kim SJ, Mitra D, Salerno JR, Hegde RS. Signal sequences control gating of the protein translocation channel in a substrate-specific manner. Developmental Cell 2(2):207-217, 2002. PMID: 11832246.
Invited Articles
- Farooqi AS, Guadagnolo BA, Mitra D, Bishop AJ. Radiation Therapy for Retroperitoneal Sarcomas: A Strass-Ful Situation. Curr Oncol 30(1):598-609, 2023. e-Pub 2023. PMID: 36661696.
- Mitra D, Bishop A, Guadagnolo BA. Adjuvant nodal radiation therapy for melanoma in the era of immunotherapy. Int J Radiat Oncol Biol Phys 108(1):164-169, 2020. e-Pub 2020. PMID: 32544573.
- Farooqi A, Mitra D, Guadagnolo BA, Bishop AJ. The Evolving Role of Radiation Therapy in Patients with Metastatic Soft Tissue Sarcoma. Curr Oncol Rep 22(8):79, 2020. e-Pub 2020. PMID: 32602007.
- Mito JK, Mitra D, Doyle LA. Radiation-Associated Sarcomas: An Update on Clinical, Histologic, and Molecular Features. Surg Pathol Clin 12(1):139-48, 2019. e-Pub 2018. PMID: 30709440.
- Mitra D, Klopp AH, Viswanathan AN. Pros and cons of vaginal brachytherapy after external beam radiation therapy in endometrial cancer. Gynecol Oncol 140(1):167-75, 2016. e-Pub 2015. PMID: 26432041.
- Mitra D, Fisher DE. Transcriptional regulation in melanoma. Hematol Oncol Clin North Am 23(3):447-65, viii, 2009. PMID: 19464596.
Editorials
- Mitra D, Robinson KC, Fisher DE. Melanoma and viagra: an unexpected connection. Pigment Cell & Melanoma Research 24(1):16-18, 2011. PMID: 21290790.
Abstracts
- Sharafi Setareh C, Guadagnolo BA, Nelson KC, Mitra D. Adjuvant Radiation Therapy in Desmoplastic Melanoma: A Scoping Review. Cancers 16(22):3874, 2024. PMID: None.
- Arifin AJ, Jerez O, Keatts S, Salem AFM, Farooqi A, Bishop AJ, Yoder AK, Goepfert RP, Weiser R, Amaria R, McQuade J, Ross MI, Guadagnolo BA, Mitra D. Adjuvant Primary Site Radiation Therapy for Melanoma in the Immunotherapy Era. Int J Radiat Oncol Biol Phys 120(2):S179-S180, 2024. PMID: None.
- Salem AFM, Chen M, Williams MD, Swanson D, McQuade J, Amaria R, Farooqi A, Bishop AJ, Hanna EY, Guadagnolo BA, Su SY, Mitra D. Sinonasal Melanoma Outcomes After Neoadjuvant Immunotherapy. Int J Radiat Oncol Biol Phys 120(2):e483-e484, 2024. PMID: None.
- Keatts S, Swanson A, Farooqi A, Bishop AJ, Amaria J, McQuade J, Glitza I, Diab A, Weiser R, Fisher S, Ross MI, Guadagnolo BA, Mitra D. Hypofractionated Radiation Therapy for Unresectable or Bulky Metastatic Melanoma. Int J Radiat Oncol Biol Phys 120(2):S180-S181, 2024. PMID: None.
- Dudzinski SO, Farooqi A, Roy S, Bishop AJ, Swanson D, Nagarajan P, Amaria R, McQuade J, Weiser R, Fisher S, Ross MI, Guadagnolo BA, Mitra D. Evaluation of Genomic and Pathologic Features Associated with Outcomes among Patients with Sentinel Lymph Node-Positive Melanoma in the Contemporary Era. Int J Radiat Oncol Biol Phys 120(2):S180, 2024. PMID: None.
- Arifin A, Bishop AJ, Mitra D, Araujo D, Haddad Nassif EF, Ratan R, Livingston JA, Lewis V, Lin P, Moon B, Keung E, Roland CL, Scally C, Guadagnolo BA, Farooqi A. Outcomes Following Combined Modality Treatment to the Primary Site in Patients with Metastatic Soft Tissue Sarcoma. Int J Radiat Oncol Biol Phys 120(2):e426-e427, 2024. PMID: None.
- Onuma A, Malik N, Cope B, Aung P, Morey R, Ingram D, Arunkumar V, Chiang Y, Mitra D, Witt R, Keung E. Assessing the 10% rule in Sentinel Lymph Nodes Biopsy in Merkel Cell Cancer. Ann Surg Oncol 31(Suppl 1):1-294, 2024. PMID: None.
- Yoder AK, Netherton T, Wang XA, Lim TY, Wang H, Luo D, Wang C, Thrower SL, Farooqi A, Mitra D, Bishop AJ, Guadagnolo BA. Evaluating the Utility of Traditional Bowel Dose Constraints When Treating Abdominal and Pelvic Sarcomas with Preoperative Radiation Therapy. International Journal of Radiation Oncology, Biology, Physics 117(2):E353-E354, 2023. PMID: None.
- Mitra D, Gonzalez C, Swanson D, Bishop AJ, Farooqi A, Garden AS, Morrison WH, Goepfert RP, Esmaeli B, Ross MI, Wong MK, Ivan D, Guadagnolo BA. Adjuvant radiation therapy improves local control in the treatment of adnexal carcinoma. International Journal of Radiation Oncology, Biology, Physics 117(2):e325-e326, 2023. PMID: None.
- Mitra D, Ologun G, Bishop AJ, Goepfert RP, Keung E, Amaria R, Wargo J, Guadagnolo BA. Nodal Recurrence Rates for Melanoma Patients With ≥1 mm Sentinel Lymph Node Involvement in the Era of Adjuvant Immunotherapy. International Journal of Radiation Oncology 108(3):E1, 2020. PMID: None.
- Mitra D, Horick N, Brackett DG, Mouw K, Hornick JL, Hong TS, Ryan DP, Parikh AR, Clark JW, Deshpande V, Wo JY. The immune milieu of anal squamous cell carcinoma: IDO expression is correlated with poor outcome. Journal of Clinical Oncology 102(3), 2018. PMID: None.
- Mitra D, Agarwal V, Chen YH, Baldini EH, Barbie DA, Chen AB, Glass B, Beck A, Herman G, Kozono DE, Schoenfeld JD, Mak RH. The prognostic significance of PDL1 expression in locally advanced non-small-cell lung cancer treated with definitive intent. Journal of Clinical Oncology, 2018. PMID: None.
- Mitra D, Mito J, Barysauskas CM, Raut CP, Doyle L, Baldini EH. Outcomes for Localized Radiation-Associated Sarcoma (RAS), Excluding Breast Angiosarcoma. International Journal of Radiation Oncology 99(2):755-6, 2017. PMID: None.
- Mitra D, Hong TS, Horick N, Rose B, Drapek LN, Blaszkowsky LS, Allen JN, Kwak EL, Murphy JE, Clark JW, Ryan DP, Cusack JC, Bordeianou LG, Berger DL, Wo JY. Long term outcomes and toxicity of anal cancer patients treated per RTOG 0529. Adv Radiat Oncol 2(2):110-117, 2017. PMID: None.
- D Mitra D, NC Cimbak NC, LJ Lee LJ, Viswanathan AA. Lymphedema: Is It Associated With Lymph-Node Involvement in Endometrial Cancer?. International Journal of Radiation Oncology 90(1):716-7, 2014. PMID: None.
- Mitra D, Nout R, Creutzberg C, Lee L, Cimbak N, Viswanathan A. Does vaginal brachytherapy (VB) boost after external beam radiation therapy (EBRT) increase rectal bleeding? Comparing results of combined EBRT+VB to PORTEC-2 data for EBRT alone and VB alone. International Journal of Radiation Oncology 90(1), 2014. PMID: None.
- Mitra D, Cimbak N, Damato AL, Lee L, Viswanathan A. Vaginal cuff brachytherapy after external beam radiation is not associated with a dose-related increase in late toxicities. Brachytherapy 13:77, 2014. PMID: None.
- Mitra D, Shih HA, Oh KS, Brastianos PK, Wo JY, Curry WT, Clark JW, Parikh AR, Corcoran R, Ryan DP, Lennerz JK, Hong TS. Her2 positivity in brain metastases from gastrointestinal primary malignancies. Journal of Clinical Oncology 14(2), 2014. PMID: None.
- Mitra D, Luo X, Morgan A, Wargo J, Fisher DE. Why redheads are at increased risk of melanoma: A novel BRAF mutant mouse model. American Association for Cancer Research 71(18), 2011. PMID: None.
Book Chapters
- Yoder AK, Mitra D, Guadagnolo BA. Melanoma. In: Pocket Radiation Oncology. 2nd. None, None.
- Yoder AK, Mitra D, Bishop AJ, Guadagnolo BA. Merkel Cell Carcinoma. In: Pocket Radiation Oncology. 2nd. None, None.
- Yoder AK, Mitra D, Guadagnolo BA. Non-Melanoma Skin Cancer. In: Pocket Radiation Oncology. 2nd. None, None.
Letters to the Editor
- Mitra D, Guadagnolo BA. Nodal Radiotherapy for Anorectal Melanoma: Finding the Appropriate Time and Place. Int J Radiat Oncol Biol Phys 120: 929-930, 2024.
Grant & Contract Support
| Title: | FLASH-RT: A novel approach for cutaneous melanoma |
| Funding Source: | Sabin Family Foundation |
| Role: | PI |
| Title: | Prediction of Radiation Therapy Associated Toxicity to Correct a Race-Based Disparity |
| Funding Source: | Radiological Society of North America (RSNA) |
| Role: | PI |
| Title: | Study on Ultra- high dose rate radiotherapy for any cutaneous or subcutaneous tumor |
| Funding Source: | Radiation Oncology Strategic Initiatives (ROSI) |
| Role: | PI |
| Title: | Preparation for a first-in- human phase I clinical trial of electron FLASH-RT |
| Funding Source: | MD Anderson Cancer Center |
| Role: | PI |
| Title: | Comparing superficial tissue toxicity with FLASH-RT vs. CONV-RT |
| Funding Source: | MD Anderson Department of Radiation Oncology |
| Role: | PI |
| Title: | Evaluating a multimodality platform of tissue, blood and advanced imaging-based biomarkers to predict response to neoadjuvant immunotherapy and radiotherapy in melanoma |
| Funding Source: | NIH |
| Role: | PI |
| Title: | Post- operative radiation therapy for high risk sentinel lymph node positive melanoma patients planned for immunotherapy |
| Funding Source: | Radiation Oncology Strategic Initiatives (ROSI) |
| Role: | PI |
| Title: | Institutional Career Development Core (CTSA-KL2) |
| Funding Source: | National Center for Advancing Translational Sciences (NCATS) |
| Role: | PI |
| Title: | Investigate the effect of HANRT for high risk SLN+ melanoma patients receiving adjuvant anti-PD1 in the absence of CLND. In addition, identify predictive biomarkers of treatment-associated toxicity and disease recurrence for SLN+ melanoma patients receiving adjuvant anti-PD1 with and without HANRT |
| Funding Source: | Radiation Oncology Strategic Initiatives (ROSI) |
| Role: | PI |
| Title: | MD Anderson Melanoma SPORE |
| Funding Source: | National Cancer Institute (NCI) |
| Role: | PI |
| Title: | Radiation therapy in immune checkpoint inhibitor resistant head and neck cancer |
| Funding Source: | American Society of Clinical Oncology (ASCO) |
| Role: | PI |
| Title: | Investigating the immunomodulatory effects of radiation with and without immune checkpoint inhibition in squamous cell carcinoma of the head and neck |
| Funding Source: | American Society for Therapeutic Radiology and Oncology (ASTRO) |
| Role: | PI |
| Title: | The role of ultraviolet radiation and skin pigmentation in melanoma development |
| Funding Source: | National Institute of Environmental Health Sciences |
| Role: | PI |
Patient Reviews
CV information above last modified November 20, 2024